Emmaus Life Sciences, Inc. (OTCQB: EMMA), a biopharmaceutical company focused on the treatment of sickle cell disease, announced its financial results for the year ended December 31, 2025, revealing a significant 25% decline in net revenues compared to the previous year. The company reported net revenues of $12.5 million, down from $16.7 million in 2024. This decline is attributed primarily to increased competition from generic L-Glutamine in the U.S. market, which has impacted sales. However, the company noted a partial offset from increased sales in the Middle East North Africa (MENA) region.

Despite the revenue drop, Emmaus reported an income from operations of $0.2 million, a notable improvement from a loss of $1.9 million in 2024. This turnaround was largely due to a 34% reduction in operating expenses, which totaled $11.4 million for the year. The company has undertaken strategic changes to enhance its U.S. operations, including a licensing and exclusive distribution agreement with NeoImmuneTech, Inc., expected to be fully implemented in the second quarter of 2026.

Emmaus also reported a net loss of $7.2 million for 2025, compared to a net loss of $6.5 million in 2024. The increase in net loss was primarily due to higher other expenses, which totaled $7.5 million, up from $4.5 million the previous year. The company cited increases in loss on debt extinguishment and interest expenses as contributing factors.

Looking ahead, Emmaus is optimistic about its international market potential and is focusing on strategic initiatives to drive growth. The company ended the year with cash and cash equivalents of $2.1 million, an increase from $1.4 million at the end of 2024. As Emmaus navigates these challenges, its leadership remains committed to enhancing operational execution and exploring new opportunities in the biopharmaceutical landscape.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.